Randomized Trial of the Effectiveness of Topical "ABH Gel" vs. Placebo in Cancer Patients With Nausea

Last updated: October 15, 2015
Sponsor: Virginia Commonwealth University
Overall Status: Completed

Phase

N/A

Condition

Lactose Intolerance

Vomiting

Colic

Treatment

N/A

Clinical Study ID

NCT01556932
MCC-14141
NCI-2012-00220
  • Ages > 18
  • All Genders

Study Summary

This randomized clinical trial studies ABH (lorazepam, diphenhydramine hydrochloride, and haloperidol) gel in patients with nausea. ABH gel, when absorbed into the skin, may be an effective treatment for nausea and vomiting. The general purpose of this research study is to improve the treatment of nausea and vomiting.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • English speaking

  • No allergies to the drugs

  • Able to complete the forms

  • If a woman of childbearing age, agree to use contraception; women will be offered apregnancy test before doing the trial if they request one, as stated in the InformedConsent Form

  • Patients must have a self reported nausea score of at least 4 on a numeric ratingscale of 0-10 (zero being no nausea and ten being the worst possible nausea); patientsare not required to have vomiting

  • Patients must have had or have cancer, or have had a consultation with the palliativecare team

  • They must not have had any changes to their nausea program within the past 12 hours,if on anti-emetics

  • Patients must not have received chemotherapy within 5 days, unless it is a stable oralchemotherapy drug such as capecitabine (Xeloda), erlotinib (Tarceva), or similar

Exclusion

Exclusion Criteria:

  • History of substance abuse, psychiatric disorder, acquired brain injury, thepossibility of pregnancy (not using birth control, and of child bearing age)

  • Use of any medication that would contraindicate benzodiazepine administration

  • Pregnant or nursing

  • Children

Study Design

Total Participants: 22
Study Start date:
March 01, 2012
Estimated Completion Date:
May 31, 2014

Study Description

PRIMARY OBJECTIVES:

I. The primary outcome is the change in numeric rating scale in self-reported nausea on a 0-10 scale from baseline to 60 minutes of treatment.

OUTLINE: All individuals who are eligible are randomized to a sequence of treatments: either placebo-ABH or ABH-placebo. The randomization list will be generated by the Study Biostatistician. Neither the patient nor the investigator will have knowledge of the actual content of Drug A or B, so the study will be double-blinded, and placebo controlled.

Drug A: The dose of the drugs in the 1.0 mL dose will be 2 mg of lorazepam, 25 mg of diphenhydramine, and 2 mg of haloperidol in a pluronic lecithin organogel. It will be rubbed on the volar surface of the wrists by the subject, for 2 minutes as done in clinical practice, at time 0. Drug B: equivalent but no ABH.

Subjects will rub 1 mL of the first drug, Drug A gel, between their wrists for 2 minutes.

Subjects will be asked to rate and complete their nausea on the Memorial Symptom Assessment Scale (CMSAS). At time 60 two options can occur. One, if there is no effect after the first drug in one hour, then patients will receive the second drug. If there is no effect in one hour from second drug, patients will stop the study and resume normal treatment for their nausea. Or two, if the first gel reduces nausea by more than 1 point on the 0-10 scale, subjects will wait 4 hours to apply the next gel. At this point, the study procedures will be repeated. After treatment, patients are followed up for up to 8 hours.

Subjects will be asked to rate their nausea on a 0 (no nausea) to 10 (worst possible nausea) scale at baseline, 60, 120, 180, and 240 minutes.

Subjects will complete the Memorial Symptom Assessment Scale (CMSAS), a reliable and valid instrument for assessing relevant symptoms including lack of energy, lack of appetite, pain, dry mouth, weight loss, feeling drowsy, shortness of breath, constipation, difficulty sleeping, difficulty concentrating, and nausea.

Connect with a study center

  • Virginia Commonwealth University

    Richmond, Virginia 23298
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.